good finish bridg
goal focu
organ sale growth ep beat
revenu y/i our/street est
management provid clean core growth vs estimate fx sale vs
estimate vs estimate euroimmun
organ growth non-gaap gm vs estim
oper margin came expect due fx higher start-up
cost relat new busi initi non-gaap opm
estimate adj ep vs guid street estimate
solid without hiccup issu
stronger organ sale growth driven diagnost segment
core growth incl core busi demand broad-bas
mostli driven reproduct health genom servic howev rest
print less clean margin fell short target euroimmun came light
due larg custom adjust order time guid also
light core growth assum possibl hit us government shutdown
due export approv delay note first lst compani cite
issu given secur natur product involv like widespread
go
pki guid organ sale growth opm
y/i adj ep roughli in-lin est impli
signific ramp hit previous discuss target hsd core sale growth
around opm think guid like conserv model
core rev remain seen vanadi deliv euroimmun continu
current pace
updat estim stay neutral rais po
reiter neutral rate await clariti pki new growth profil
beyond adjust revenu est rais ep estimate
vs prior lower interest expens po goe still
ep in-lin peer
full definit iqmethod sm measur see page
net dbt
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart waltham massachusett
found diversifi
provid scientif instrument consum
servic address basic appli
research well signific global health
safeti issu includ matern fetal health
food safeti environment monitor today
compani oper two segment
environment
diversifi provid
scientif instrument consum servic
think compani tact piec
togeth numer acquir asset sinc
form uniqu comprehens solut
custom nich market posit
portfolio transform improv
growth profil believ compani still
face near-term headwind share
like rang bound
po base ep estim in-lin compani
broader lst diagnost peer group multipl signific premium
histor multipl due improv core growth margin think
multipl appropri given on-going oper improv improv
growth profil compani
upsid risk po better expect organ sale growth margin
expans faster uptak new product capit deploy option
acquisit compani
downsid risk competit execut integr risk weaker macro
environ fx swing fund cut slower expect uptak new
product regulatori risk reiter neutral rate
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
invest opinion system contain end report head fundament equiti opinion dark grey shade indic secur restrict opinion suspend medium grey
shade indic secur review opinion withdrawn grey shade indic secur cover chart current decemb later date indic
equiti invest rate distribut health group dec
equiti invest rate distribut global group dec
issuer invest bank client bofa merril lynch one affili within past month purpos invest rate distribut coverag univers includ stock
stock rate neutral includ hold stock rate under-perform includ sell
fundament equiti opinion opinion includ volatil risk rate invest rate incom rate volatil risk rate indic potenti
price fluctuat medium high invest rate reflect analyst assess stock absolut total return potenti ii
attract invest rel stock within coverag cluster defin three invest rate buy stock expect total
return least attract stock coverag cluster neutral stock expect remain flat increas valu less attract
buy rate stock under-perform stock least attract stock coverag cluster analyst assign invest rate consid among thing
month total return expect stock firm guidelin rate dispers shown tabl current price object stock
referenc better understand total return expect given time price object reflect analyst view potenti price appreci depreci
total return expect within period date initi rate
rate dispers guidelin coverag cluster
